Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tonghua Dongbao Medicines To Expand Insulin Production

This article was originally published in PharmAsia News

Executive Summary

Tonghua Dongbao Medicines has begun the second phase of expanding its 3,000 kg recombinant human insulin (lyophilized powder) project. Meanwhile, the company reveals that it will invest 80 million yuan in the next half year to set up the new facility to output 30 million human insulin injections annually. Figures show that China's total insulin injections retailed last year reached 3 billion yuan or about 50 million doses, with 90 to 95 percent of the market dominated by pharmaceutical MNCs such as Novo Nordisk and Eli Lilly. Because of the considerable expense in promoting insulin injections, analysts believe Dongbao will face tough competition increasing its sales from the current 3 million injections to a possible 38 million injections. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069445

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel